Microneedle Drug Delivery Systems Market Outlook:
Microneedle Drug Delivery Systems Market size was valued at USD 4.23 billion in 2025 and is expected to reach USD 8.4 billion by 2035, expanding at around 7.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of microneedle drug delivery systems is evaluated at USD 4.5 billion.
The market is estimated to grow on the back of the increasing prevalence of chronic conditions such as diabetes, cancer, heart disease, and stroke. According to the International Diabetes Federation, around 589.0 million adults aged between 20 and 79 were affected by diabetes worldwide, which is projected to reach 853.0 million by 2050. Another NLM prediction revealed that the annual count of new and death cases of cancer is poised to be 26.0 million and 17.0 million by 2030, respectively. On the other hand, several studies have shown improved results from using this type of therapy in managing these diseases. In addition, the wide use of microneedling in dermatology, such as removing acne scars, is also fueling growth in this sector.
As per NLM, the net global cost of chronic ailments has the potential to attain USD 47.0 trillion by 2030. Thus, the magnifying economic burden on patients with such illnesses is pushing the market to curate more accessible solutions with lower payers’ pricing. In selective cases, its therapeutic approach has also been proven to be a value-based solution. On this note, a publication from the Indian Association of Dermatologists, released in February 2025, established microneedling as a more cost-effective alternative to autologous platelet-rich plasma (PRP) treatment for acne scars. The study testified this fact with the associated benefits, including fewer side effects and quicker recovery, where PRP resulted in post-inflammatory hyperpigmentation among 10.0% of candidates.
